The "Activation of sigma-1 receptor chaperone in the treatment of neuropsychiatric diseases and its clinical implication" paper suggests, like the one I referred to earlier, that the positive effect of Donepezil could be related to its agonist effect on S1R.
We have to see if getting rid of the baggage of DZP and cleanly using the S1R agonism of A2-73 along with M1 modulation is the secret to success.
So far though the data from Anavex appears to conclude that A2-73 co-administration with DZP makes little difference to outcomes. What is up an down in these findings is so far hard to penetrate.
Market Data 
Markets 
AI
